{
    "clinical_study": {
        "@rank": "92568", 
        "arm_group": {
            "arm_group_label": "All participants", 
            "arm_group_type": "Experimental", 
            "description": "Participants will receive MK-5172, 100 mg tablet, orally once per day (QD) for 12 weeks; MK-8742, 50 mg tablet, orally, QD for 12 weeks; RBV capsules, 800-1400 mg weight-based dose, orally, twice per day (BID) for 12 weeks"
        }, 
        "brief_summary": {
            "textblock": "In this study, participants with hepatitis C virus (HCV) genotype 1 (GT1) who failed prior\n      direct-acting antiviral (DAA) therapy will receive MK-5172 + MK-8742 + Ribavirin (RBV) to\n      evaluate sustained virologic response (SVR) using this drug combination."
        }, 
        "brief_title": "Study of MK-5172 + MK-8742 + Ribavirin in Participants With Chronic Hepatitis C Who Failed Prior Direct-Acting Antiviral Therapy (MK-5172-048)", 
        "completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "condition": "Hepatitis C Virus", 
        "condition_browse": {
            "mesh_term": [
                "Hepatitis", 
                "Hepatitis A", 
                "Hepatitis, Chronic", 
                "Hepatitis C", 
                "Hepatitis C, Chronic"
            ]
        }, 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion criteria:\n\n          -  Documented chronic HCV GT1 infection (with no evidence of non-typable or mixed\n             genotype)\n\n          -  Absence of cirrhosis, or cirrhosis with these criteria: METAVIR F4, or Fibroscan with\n             result >12.5 kPa, or FibroSure\u00ae (Fibrotest\u00ae) score of >0.75 + aspartate\n             aminotransferase (AST): platelet ratio index (APRI) of >2- Prior regimen containing\n             an approved DAA (boceprevir, telaprevir, simeprevir, or sofosbuvir), pegylated\n             interferon, and/or ribavirin\n\n          -  Participants of reproductive potential must agree to remain truly abstinent or use\n             (or have their partner use) 2 acceptable methods of birth control from at least 2\n             weeks prior to Day 1 and continue until at least 6 months after last dose of study\n             drug, or longer if dictated by local regulations\n\n        Exclusion criteria:\n\n          -  Received any HCV regimen containing a DAA with the exception of boceprevir,\n             telaprevir, simeprevir, or sofosbuvir in combination with pegylated interferon and/or\n             ribavirin\n\n          -  Evidence of decompensated liver disease or cirrhosis\n\n          -  Co-infected with hepatitis B virus or human immunodeficiency virus (HIV)\n\n          -  History of malignancy <=5 years prior to signing informed consent except for\n             adequately treated basal cell or squamous cell skin cancer or in situ cervical cancer\n             or carcinoma in situ; or under evaluation for other active or suspected malignancy\n\n          -  Evidence of hepatocellular carcinoma (HCC) or under evaluation for HCC\n\n          -  Currently participating or has participated in a study with an investigational\n             compound within 30 days of signing informed consent and is not willing to refrain\n             from participating in another such study during the course of this study\n\n          -  Clinically-relevant drug or alcohol abuse within 12 months of screening\n\n          -  Pregnant, breast-feeding, or expecting to conceive or donate eggs or sperm from at\n             least 2 weeks prior to Day 1 and continue throughout treatment and follow up,  or\n             longer if dictated by local regulations\n\n          -  Male participant whose female partner (s) is/are pregnant\n\n          -  Organ transplants (including hematopoietic stem cell transplants) other than cornea\n             and hair\n\n          -  Poor venous access\n\n          -  History of gastric surgery (e.g., stapling, bypass) or history of malabsorption\n             disorders (e.g., celiac sprue disease)\n\n          -  Hemoglobinopathy, including, but not limited to, thalassemia major\n\n          -  Any medical condition requiring, or likely to require, chronic systemic\n             administration of corticosteroids during the course of the trial\n\n          -  Evidence or history of chronic hepatitis not caused by HCV, including but not limited\n             to nonalcoholic steatohepatitis (NASH), drug-induced hepatitis, and autoimmune\n             hepatitis"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "No", 
            "maximum_age": "N/A", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "80", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "April 2, 2014", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT02105454", 
            "org_study_id": "5172-048", 
            "secondary_id": "2013-004213-41"
        }, 
        "intervention": [
            {
                "arm_group_label": "All participants", 
                "intervention_name": "MK-5172", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "All participants", 
                "intervention_name": "MK-8742", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "All participants", 
                "intervention_name": "Ribavirin", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": [
                "Antiviral Agents", 
                "Ribavirin"
            ]
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "Yes", 
        "lastchanged_date": "May 29, 2014", 
        "location": [
            {
                "facility": {
                    "address": {
                        "city": "Detroit", 
                        "country": "United States", 
                        "state": "Michigan", 
                        "zip": "48202"
                    }, 
                    "name": "Call for Information (Investigational Site 0004)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "Hillsborough", 
                        "country": "United States", 
                        "state": "New Jersey", 
                        "zip": "08844"
                    }, 
                    "name": "Call for Information (Investigational Site 0009)"
                }, 
                "status": "Recruiting"
            }, 
            {
                "facility": {
                    "address": {
                        "city": "San Antonio", 
                        "country": "United States", 
                        "state": "Texas", 
                        "zip": "78215"
                    }, 
                    "name": "Call for Information (Investigational Site 0005)"
                }, 
                "status": "Recruiting"
            }
        ], 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "1", 
        "official_title": "A Phase II Clinical Trial to Study the Efficacy and Safety of the Combination Regimen of MK-5172 + MK-8742 + Ribavirin (R) in Subjects With Chronic Hepatitis C Virus Infection Who Failed Prior Direct Acting Antiviral Therapy", 
        "overall_contact": {
            "last_name": "Toll Free Number", 
            "phone": "1-888-577-8839"
        }, 
        "overall_official": {
            "affiliation": "Merck Sharp & Dohme Corp.", 
            "last_name": "Medical Director", 
            "role": "Study Director"
        }, 
        "overall_status": "Recruiting", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 2", 
        "primary_completion_date": {
            "#text": "June 2015", 
            "@type": "Anticipated"
        }, 
        "primary_outcome": [
            {
                "measure": "Percentage of participants achieving SVR at 12 weeks after the end of all study therapy (SVR12)", 
                "safety_issue": "No", 
                "time_frame": "Up to 24 weeks"
            }, 
            {
                "measure": "Number of participants experiencing adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 36 weeks"
            }, 
            {
                "measure": "Number of participants discontinuing study drug due to adverse events", 
                "safety_issue": "Yes", 
                "time_frame": "Up to 12 weeks"
            }
        ], 
        "removed_countries": {
            "country": "Austria"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT02105454"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": {
            "measure": "Percentage of participants achieving SVR12 by prior DAA therapy", 
            "safety_issue": "No", 
            "time_frame": "Up to 24 weeks"
        }, 
        "source": "Merck Sharp & Dohme Corp.", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Merck Sharp & Dohme Corp.", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2014", 
        "study_design": "Endpoint Classification: Safety/Efficacy Study, Intervention Model: Single Group Assignment, Masking: Open Label, Primary Purpose: Treatment", 
        "study_type": "Interventional", 
        "verification_date": "May 2014"
    }
}